scholarly journals Hyperparathyroidism Two Years after Radioactive Iodine Therapy in an Adolescent Male

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Danielle L. Gomez ◽  
Dorothy I. Shulman
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Primary Hyperparathyroidism ◽  
Radioactive Iodine ◽  
Rare Complication ◽  
Latency Period ◽  
Adolescent Male ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Iodine Treatment

Primary hyperparathyroidism is a very rare complication following radioactive iodine therapy. There is typically a latency period of more than a decade following radiation exposure and, therefore, it is observed almost exclusively in adults. Consequently, pediatricians are not aware of the association. We present a case of primary hyperparathyroidism due to a solitary parathyroid adenoma occurring in an adolescent male two years following radioactive iodine treatment for papillary thyroid carcinoma. Periodic screening of serum calcium following ablative doses of radioactive iodine for thyroid cancer may be justified even in adolescents.

Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma

2016 ◽  
Vol 82 (9) ◽  
pp. 807-814 ◽  
Author(s):  
Paritosh Suman ◽  
Chi-Hsiung Wang ◽  
Tricia A. Moo-Young ◽  
Richard A. Prinz ◽  
David J. Winchester
Keyword(s):  
Overall Survival ◽  
Survival Analysis ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Low Risk ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid ◽  
Risk Patients

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI) therapy in low- and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the impact of adjuvant RAI on overall survival (OS) in low- and intermediate-risk PTC. The National Cancer Data Base was queried from 2004 to 2011 for pN0M0 PTC patients having near/subtotal or total thyroidectomy and adjuvant RAI. Tumors ≤1 cm with negative margins were low risk while 1.1- to 4-cm tumors with negative margins or ≤1 cm with microscopic margins were termed intermediate risk. RAI in ≤3 months and between 3 and 12 months was termed as early and delayed, respectively. Survival analysis was performed after adjusting for patient and tumor-related variables. There were 7,306 low-risk and 16,609 intermediate-risk patients. Seventeen per cent low-risk and 15 per cent intermediate-risk patients had delayed RAI. Kaplan-Meier analysis did not show a difference in OS for early versus delayed RAI administration in low- (10-year OS 94.5% vs 94%, P = 0.627) or intermediate-risk (10-year OS 95.3% vs 95.9%, P = 0.944) patients. In adjusted survival analysis, RAI timing did not affect OS in all patients (hazard ratios = 0.98, 95% confidence interval = 0.71–1.34, P = 0.887). In conclusion, the timing of postthyroidectomy adjuvant RAI therapy does not affect OS in low- or intermediate-risk PTC.

scholarly journals Management of Papillary Carcinoma of Thyroid with Pulmonary Metastases in Institute of Nuclear Medicine and Allied Sciences, Rajshahi – Two Case Reports

2018 ◽  
Vol 18 (2) ◽  
pp. 179-182
Author(s):  
Md Kabiruzzaman Shah ◽  
Nasrin Begum ◽  
Mosharof Hossain ◽  
Parvez Ahmed ◽  
Sariful Islam Chawdhuary ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Radioactive Iodine ◽  
Pulmonary Metastases ◽  
Case Reports ◽  
Young Patients ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Papillary thyroid carcinoma with pulmonary metastasis is relatively uncommon which can be treated with radioactive iodine therapy. Here, our experiences with two cases of papillary thyroid carcinoma with pulmonary metastases in young patients are discussed.Bangladesh J. Nuclear Med. 18(2): 179-182, July 2015

Sign in / Sign up

Export Citation Format

Share Document